Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Travere Therapeutics Inc

TVTX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$65.28

▼ -1.89%

Market Cap $6.15B · Vol 339.68K

Key Metrics

P/E Ratio

N/A

FWD: 40.08

Market Cap

$6.15B

Mid Cap

Div Yield

N/A

EPS Growth

+18.53%

YoY

RSI (14)

56.05

Momentum

Beta

1.13

vs Market

52W High

$68.01

4.01% below

52W Low

$20.85

213.09% above

Volume

339.68K

Avg 518.42K

P/B

30.26

Price-to-book

ROE

N/A

Return on equity

Free Float

94.86%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Travere Therapeutics Inc (TVTX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TVTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.59%

+16.53%

+41.36%

+131.65%

YTD

+70.85%

+208.65%

+360.04%

+208.94%

Financials & Valuation

TTM · Annual

Total Revenue	$490.73M
Net Income	$-50,261,000.00
Revenue Growth (YoY)	+48.17%
Gross Margin	97.89%
Operating Margin	-12.80%
Net Profit Margin	-10.24%
ROE	N/A
ROA · ROIC	-8.22% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	40.08
PEG Ratio	N/A
P/S	6.95
P/B	30.26
P/FCF	N/A
EPS Growth	+18.53%
Outstanding Shares	94.26M

Technical Indicators

50-Day SMA	$60.26
200-Day SMA	$42.42
RSI (14)	56.05
Beta	1.13
52-Week High	$68.01
52-Week Low	$20.85

Volume Today	339.68K
Avg Daily Volume (30D)	518.42K
Relative Volume	0.66x
Volatility (10D)	26.22
Volatility (30D)	42.70
Free Float	94.86%

Analyst Consensus

BUY

Current Price $65.28

Mean Target $72.92

52W Low$20.85 52W High$68.01

Current

Target

$20.85 $68.01

Current Analyst target

+11.71% upside potential · 15 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SL72C5

ISINUS89422G1076

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateOct 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.57% ARGX.BR argenx SE -2.06% ARGX argenx SE -1.93% INSM Insmed Inc -0.31% 2269.HK WuXi Biologics (Cayman) Inc -3.00%

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.